Computershare has wrapped up its $750 million on-market share buy-back, cancelling over 25 million shares and signaling a strategic pivot towards dividends as the preferred shareholder reward.
Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.